Allarity Therapeutics maintained a Buy rating by Ascendiant
Ascendiant Capital maintained its Buy rating on Allarity Therapeutics, per a Benzinga ratings-action update.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.